<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203694</url>
  </required_header>
  <id_info>
    <org_study_id>2008181</org_study_id>
    <nct_id>NCT03203694</nct_id>
  </id_info>
  <brief_title>Effects of Walking and Heating on Vascular Function in Diabetic Patients</brief_title>
  <official_title>Restoring Vasodilator Actions of Insulin in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to determine the effects of increased walking and lower
      body heating on leg vascular function in patients with type 2 diabetes (T2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The notion that habitual aerobic exercise increases insulin-induced vasodilation is largely
      founded on rodent studies, hence the urgent need for human studies, especially in patients
      with type 2 diabetes (T2D). For example, it remains unknown if increased walking, the most
      common form of physical activity, enhances skeletal muscle vasodilator actions of insulin in
      T2D. In addition, the molecular mechanisms by which exercise improves vasoreactivity to
      insulin have not been examined in humans. The investigators propose that in T2D patients who
      are sedentary (i.e., the vast majority), increased leg blood flow with walking or local
      heating signifies a vital strategy to correct vascular insulin resistance. This study will
      establish whether increased physical activity and associated hemodynamic forces (e.g., shear
      stress) are a direct form of vascular medicine in humans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned to either a walking, lower body heating, or no intervention for 8 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>Flow-mediated dilation will be measured at baseline and at 8 weeks following intervention</time_frame>
    <description>Flow-mediated dilation in arm and leg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood flow</measure>
    <time_frame>Change from baseline blood flow will be measured at the end of session 1 and at 8 weeks following intervention</time_frame>
    <description>Measure of blood flow during insulin clamp and oral glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>Change from baseline glucose disposal rate will be measured at the end of session 1 and at 8 weeks following intervention</time_frame>
    <description>Measure of glucose disposal rate during insulin clamp</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Walking intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will be instructed to continue their usual lifestyle for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower body heating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This intervention consists of 45-60 minutes of lower body heating (40-42 degree C) 4 days per week for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Walking</intervention_name>
    <description>The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.</description>
    <arm_group_label>Walking intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lower body heating</intervention_name>
    <description>This intervention consists of 45-60 minutes of lower body heating (40-42 degree C) 4 days per week for 8 weeks.</description>
    <arm_group_label>Lower body heating</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with type 2 diabetes who are overweight and obese (BMI 25-50 kg/m2), 35 to 65
        years of age, and sedentary (&lt;60 minutes structured exercise/week). Healthy volunteers
        without type 2 diabetes: 35 to 65 years of age.

        Exclusion Criteria:

          1. Cardiovascular disease including myocardial infraction, heart failure, coronary artery
             disease, stroke;

          2. renal or hepatic diseases;

          3. active cancer;

          4. autoimmune diseases;

          5. immunosuppressant therapy;

          6. excessive alcohol consumption (&gt;14 drinks/week for men; &gt;7 drinks/week for women);

          7. current tobacco use;

          8. pregnancy;

          9. mobility limitations;

         10. foot ulcers;

         11. diabetic neuropathy

         12. uncontrolled hypertension (&gt;=180 systolic / 100 diastolic mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaume Padilla, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaume Padilla, PhD</last_name>
    <phone>812 3453566</phone>
    <email>padillaja@missouri.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Padilla</last_name>
      <phone>573-882-7056</phone>
      <email>padillaja@missouri.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Jaume Padilla</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

